Verici Dx Plc (LON:VRCI)
0.42p
Spriggl Score: Weak— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Transplant tests growing fast, but share count up sixfold and cash runway ends this year.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, in…
- Sector:
- Healthcare
- Industry:
- Diagnostics & Research
- Market Cap:
- £6.3M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Verici Dx Plc and 1,600+ UK and US stocks.
Start free